ValueAct Gets Boost from Valeant Deal

The activist investment firm is the third largest shareholder in the pharmaceutical company, whose shares surged on news it was acquiring Bausch & Lomb.

Valeant Pharmaceuticals International’s acquisition of Bausch & Lomb for $8.7 billion in cash is a big boon for a handful of savvy hedge fund managers, especially Jeffrey Ubben.

Ubben runs the ValueAct Holdings hedge fund out of ValueAct Capital, his San Francisco–based investment firm.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Related